IL5 and hypereosinophilic syndrome: The anti-IL-5 antibody, mepolizumab, was recently shown to be an effective CS-sparing and eosinophil-lowering agent in CS-responsive HES patients with both lymphocytic and idiopathic disease variants [6-8].